VEGFA and neoplasm: Preclinical assay revealed that only aumolertinib treatment following pemetrexed (P-A) exhibited synergistic inhibition on tumor growth and metastasis, by the enhanced suppression of EGFR pathway as well as increased intratumoral accumulation of pemetrexed through aumolertinib-mediated reduction of VEGF secretion and consequently tumor vessel normalization.